AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06125964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Affect-Based Goals
Description: On days participants plan to exercise, morning and evening goal sessions ask them to provide an activity goal for the day; create a concrete plan; prompt them to anticipate barriers and brainstorm solutions; and reflect on whether they were able to meet this goal. Affect-based goals ask participants to engage in either a type or context of physical activity that allows them to experience positive affect. Goals focused on context are randomly generated to suggest that the participant performs activity in a place, in a social situation, or while listening to something that makes them feel good. For each condition, the Fitbit Versa device will feature a custom watch face with a clock (current local time), the date, current device battery levels, and an exercise button. The exercise button can be pressed whenever a subject wants to engage in physical activity, and provides real-time feedback on exercise duration while featuring a smiley face emoticon.
Study NCT06125964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TYPE/CONTEXT Enhancement
Description: The TYPE/CONTEXT enhancement will augment affect-based treatment effects by additionally providing tailored recommendations for activity types and contexts that satisfy personally important psychological needs as rated by each participant at baseline. Ratings from a crowdsourced panel of adults on Amazon Mechanical Turk were used to determine the potential for specific activity types and contexts to satisfy psychological needs; our tailoring algorithm recommends the corresponding activity type or context while accounting for reported constraints. Different psychological needs will be selected each day. Tailored recommendations are incorporated immediately following the morning goal module.
Study NCT06125964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAVOR Enhancement
Description: The SAVOR enhancement will augment affect-based treatment effects by additionally implementing a brief savoring exercise on the smartphone during the evening goal session (after the self-monitoring module). Participants will respond to questions that are intended to enhance and prolong positive experiences during physical activity. To trigger attentional deployment, a common savoring strategy that involves intensifying experiences by focusing on them, participants will answer open-ended prompts. These prompts are drawn from a prompt pool with slightly varied wording to promote a sense of novelty.
Study NCT05319977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile incentive-based intervention
Description: a technology-based behavioral intervention to address maternal alcohol use with mobile breathalyzer technology or/and urinalysis for biochemical verification of alcohol use, contingent financial incentives on alcohol abstinence, and text-based health promotion.
Study NCT06538545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting position is used in Experimental Arms 1-2
Description: sitting position Comparison of sitting position and lithotomy position in labor
Study NCT06538545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sitting position is used in Experimental Arms 1-2
Description: sitting position Comparison of sitting position and lithotomy position in labor
Study NCT04851301 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Intervention
Description: Participants will experience tonic pain tolerance tests without exposure to any environments.
Study NCT04851301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: 4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment.
Study NCT04851301 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment.
Study NCT04851301 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Natural history
Description: Participants will not be provided Naloxone or Saline.
Study NCT05827224 — intervention group
Intervention type: DEVICE
Intervention: Comfilcon A spherical soft contact lenses
Description: Commercially available silicone hydrogel contact lenses
Study NCT05827224 — intervention group
Intervention type: DEVICE
Intervention: Comfilcon A toric soft contact lenses
Description: Commercially available silicone hydrogel contact lenses
Study NCT05969353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: accupunture
Description: BFA
Study NCT05969353 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: accupunture
Description: BFA
Study NCT06721104 — intervention group
Intervention type: OTHER
Intervention: Functional Balance
Description: Functional balance will be assessed using the Timed Up and Go (TUG) test. The TUG test measures the time it takes for an individual to stand up from a chair upon the ready, go signal, walk a distance of 3 meters, turn around, walk back to the chair, and sit down again. The TUG test is a reliable and sensitive measure of balance and functional mobility in children.~At the beginning of the test, participants will be seated on an armless chair with their hips and knees flexed at approximately 90 degrees and their feet flat on the ground. The children will be instructed to stand up from the chair, walk as quickly as possible, touch a target on the wall, walk back, and sit down again.
Study NCT06721104 — intervention group
Intervention type: OTHER
Intervention: Social Adaptation Assessment
Description: Adaptive behavior will be evaluated using the Vineland Adaptive Behavior Scales. This is a parent interview designed to assess functionality in daily life. Specifically, adaptive behavior is evaluated in four domains: Communication, Daily Living Skills, Socialization, and Motor Skills. The Vineland scales are known for their reliability and up-to-date validity. They have been reported to be sensitive to the challenges faced by children with Autism Spectrum Disorder (ASD).
Study NCT06721104 — intervention group
Intervention type: OTHER
Intervention: Cervical Posture Assessment:
Description: Cervical posture will be evaluated using the Android-based PostureScreen Mobile application (version 8.5, developed by Posture Co. Inc., USA). This application assesses the static posture of individuals. After determining reference points, the application draws reference lines and records postural deviations. At least two photos of each participant will be taken for the assessment. Participants should not wear clothing items that cover the neck (e.g., scarves, shawls).~While the primary focus of the application is to assess postural deviations, it also includes a dental evaluation feature. The validity and reliability of the application have been established in previous studies. In addition to using the application, the posture of individuals will also be evaluated through observational analysis, and the findings will be documented.
Study NCT05442359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano-bio fusion gingival gel
Description: Thin coat applied to cover the palate after free gingival graft harvest. A stent will be placed to retain its effect. Patients will receive the gel to be used at home twice daily till 3rd week and once in the 4th week
Study NCT05442359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent
Description: Applied as a palatal stent for palatal wound
Study NCT04045600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trad FCT
Description: This intervention emulates a traditional reinforcement schedule-thinning method during FCT in which clinicians program delays to reinforcement without discriminative stimuli (e.g., the child learns that some FCRs result in reinforcement and some do not). By programming reinforcement approximately every 15 s, the rate of reinforcement will be equivalent to mult FCT. During Period 1 of this project, trad FCT served as an appropriate control condition to which mult FCT could be compared.
Study NCT04045600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mult FCT
Description: This intervention involves correlating discriminative stimuli (e.g., purple and yellow index cards) with times in which reinforcement for the functional communication response (FCR) is and is not available. During Period 1 of this project, this procedure resulted in rapid reduction of destructive behavior and mitigated resurgence and renewal when the discriminative stimuli were used as programmed.
Study NCT04045600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mult FCT + Stimulus Fading
Description: This condition is similar to mult FCT except that the experimenters will gradually incorporate natural stimuli (e.g., rugs, tables, lamps) into sessions to approximate target settings that may occasion relapse typically without such gradual stimulus fading.
Study NCT06361316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: Postoperative adjuvant therapy
Study NCT06538233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffered articaine
Description: Injecting buffered articaine in maxillary anterior region and evaluate pain response.
Study NCT06538233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non buffered articaine
Description: Injecting non buffered articaine in maxillary anterior region and evaluate pain response.
Study NCT06230744 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle
Description: All participants will receive diet and exercise goals and coaching.
Study NCT06230744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle II
Description: All participants will receive diet and exercise goals and coaching.
Study NCT05669625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational live attenuated varicella vaccine
Description: 0.5 ml/vial
Study NCT05669625 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of live attenuated varicella vaccine
Description: 0.5 ml/vial
Study NCT05120986 — intervention group
Intervention type: OTHER
Intervention: IND/GLY/MF
Description: Prospective observational cohort study. There is no treatment allocation. Patients will be invited to participate in the study when attending participating community pharmacies with a first prescription of IND/GLY/MF with sensor or IND/GLY/MF without sensor
Study NCT04861649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplantation
Description: The nasointestinal tube was placed and the fecal bacteria of healthy people were transplanted with liquid fecal bacteria (three transplants per course of treatment).~200ml of bacterial liquid was transplanted for each course, containing 40g of bacterial volume, transplanted consecutively for 3 times, once a day)
Study NCT06006182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape Powder
Description: Freeze-dried grape powder
Study NCT06006182 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grape Powder
Description: Freeze-dried grape powder
Study NCT05698901 — intervention group
Intervention type: DRUG
Intervention: Agalsidase beta
Description: The treatment is following local reimbursement criteria and judge by physician
Study NCT05079672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine injectable solution, at the rate of 0,3μg/ kg/h, will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.
Study NCT05079672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0,9% Saline
Description: Saline 0,9% will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by- pass.
Study NCT05709626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No aspirin (Prasugurel monotherapy)
Description: 12-month prasugrel monotherapy
Study NCT05709626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12-month DAPT
Description: 12-month dual antiplatelet therapy with prasugrel and aspirin
Study NCT05380882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2930 injection
Description: TQB2930 is an anti-HER2 bispecific antibody.
Study NCT06536699 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy - hypofractionated
Description: Hypofractionated Radiotherapy of 55 Gy in 20 fractions in definitive setting and 52.5 Gy in 20 fractions in adjuvant setting. Total duration - 4 Weeks
Study NCT06536699 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy - Conventional
Description: Conventional Radiotherapy of 66 Gy in 30 fractions in definitive setting and 60 Gy in 30 fractions in adjuvant setting. Total duration - 6 Weeks
Study NCT04759716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Literacy-based Weight Control Intervention
Description: intervention arm will be applied to receive health literacy-based mobile Health App, smart sports watch Fitbit versa during the 12 months weight control program
Study NCT06087302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: child-Parent Relationship Therapy (CPRT)
Description: The Child Parent Relationship Therapy (CPRT) is an evidence-based intervention program that trains parents/caretakers to help their children with social, emotional, attachment, and behavioral difficulties
Study NCT04766593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncological functional reeducation program
Description: It will consist of the following actions:~1. Prescription of multimodal physical exercise.~2. Retraining in activities of daily living.
Study NCT04766593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oncological functional reeducation program
Description: It will consist of the following actions:~1. Prescription of multimodal physical exercise.~2. Retraining in activities of daily living.
Study NCT06059287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin
Description: Henagliflozin 10mg qd po
Study NCT06059287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000mg bid po
Study NCT06721104 — intervention group
Intervention type: OTHER
Intervention: Temporomandibular Joint (TMJ) Assessment
Description: The TMJ will be evaluated using the Helkimo Clinical Craniomandibular Index. This index consists of five subcategories: pain during muscle palpation, pain during TMJ palpation, pain during mandibular functions, TMJ functions (sounds, gliding during maximum opening, dislocation and/or locking), and the mandibular range of motion. Each subcategory is scored as 0, 1, or 5, resulting in a total score ranging from 0 to 25.~As this index is based on performance measurements, there is no Turkish validity and reliability study for it. However, a prevalence study using this index was conducted in Turkey by Üner et al. to evaluate its applicability within the Turkish population.
Study NCT06721195 — intervention group
Intervention type: DRUG
Intervention: Remimazolam for Gastrointestinal Endoscopy Sedation
Description: This intervention involves the use of remimazolam, a short-acting benzodiazepine, for sedation during gastrointestinal endoscopy procedures (gastroscopy, colonoscopy, or both). Remimazolam is administered intravenously at an initial dose of 0.2-0.3 mg/kg, followed by additional doses of 2.5 mg as needed to maintain adequate sedation (MOAA/S score ≤ 2).~Unlike other benzodiazepines, remimazolam is rapidly metabolized by plasma esterases, resulting in a quick onset and recovery with minimal respiratory and cardiovascular depression. The study specifically evaluates the euphoria-inducing potential of remimazolam, using the ARCI-MBG scale pre- and post-procedure to assess its effect on patient comfort and satisfaction.
Study NCT06720506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: Fentanyl will be given intrathecal with dose 10-20ug
Study NCT06720506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine will given IV as shot in Dose 1mg /kg
Study NCT06721533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar rTMS
Description: Cerebellar rTMS applied to pharyngeal area of right hemisphere
Study NCT06286683 — intervention group
Intervention type: DEVICE
Intervention: lung ultrasound
Description: Used to diagnose and monitor pulmonary aeration in the context of prolonged decubitus disorders (atelectasis) via the lung ultrasound score (LUS).
Study NCT06286683 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Doppler
Description: Non-invasive, bedside method of measuring cerebral blood flow.
Study NCT06286683 — intervention group
Intervention type: DEVICE
Intervention: near-infrared spectroscopy (NIRS)
Description: Non-invasive, bedside method of cerebral oximetry that requires no advanced expertise.
Study NCT06286683 — intervention group
Intervention type: DEVICE
Intervention: clinical examination
Description: clinical examination
Study NCT06360172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing, or MI, is a collaborative, person-centered counseling technique to uncover and enhance a person\&#39;s motivation for behavior change
Study NCT06205771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H2S content
Description: H2S content
Study NCT04316338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS)
Description: Non-invasive brain stimulation technique
Study NCT05303480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlormethine
Description: Chlormethine gel 0.016%
Study NCT05982522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: orally taken once daily
Study NCT05982522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: 125 mg/m2 D1, 8 Q3W, Intravenously
Study NCT05982522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m2 D1, 8 Q3W, Intravenously
Study NCT05982522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200mg Q3W, Intravenously
Study NCT05982522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg Q3W, Intravenously
Study NCT05298176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib, Osimertinib, Carboplatin and Pemetrexed
Description: This study consists of 2 parts. Part 1 is defined as a first line treatment with afatinib orally (30 mg once a day) for the first 6 weeks, followed by concurrent use of afatinib (20mg once a day, part 1B) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by afatinib monotherapy (30mg once a day). Part 2 comprises a 2nd line treatment with osimertinib (80 mg once daily) after failure of part 1, only in T790M positive patients for the first 6 weeks, followed by concurrent use of osimertinib (80mg once a day) plus 2 cycles of carboplatin and pemetrexed (21 days per cycle); followed by osimertinib monotherapy (80mg once a day).
Study NCT05481632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoangel assisted the process of colonoscopy
Description: Endoangel assisted doctors to detect polyps
Study NCT05481632 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Colonoscopy was performed without endoangel assistance
Description: Polyps were detected without ENDOANGEL assistance
Study NCT05715788 — intervention group
Intervention type: DRUG
Intervention: Nitric oxide
Description: Nitric oxide inhalation at 20 ppm
Study NCT05715788 — intervention group
Intervention type: BEHAVIORAL
Intervention: prone positioning
Description: vatilation in prone position
Study NCT06332365 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Acetonide triamcinolone 0.2% +hyaluronicacid 1%
Description: topical application cream form twice a day for 4 weeks
Study NCT06332365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticoid Acetonide triamcinolone 0.2%
Description: topical application cream form twice a day for 4 weeks
Study NCT06332365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid 1%
Description: topical application cream form twice a day for 4 weeks
Study NCT04664283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCB for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography
Description: DCB for de Novo Lesions in Large Coronary Arteries Guided by both angiogram and Optical Coherence Tomography
Study NCT04664283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DCB for de Novo Lesions in Large Coronary Arteries Guided by Optical Coherence Tomography
Description: DCB for de Novo Lesions in Large Coronary Arteries Guided by both angiogram and Optical Coherence Tomography
Study NCT05526274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)
Description: VCTE with associated CAP is an effective, non-invasive and safe diagnostic method to estimate the degree of fibrosis and steatosis in the liver.
Study NCT06537245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage was applied in the both quads during 5 or 10 minutes, with differents pressures.
Study NCT04726761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory Blood Pressure Monitoring, frequent/non-frequent
Description: Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a frequent interval, and then a non-frequent interval.